← All Aquestive Therapeutics, INC filings

Aquestive Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
AQST
Aquestive Therapeutics, INC
10-K: Aquestive Therapeutics Faces Anaphylm Delay, Libervant Setback
Aquestive Therapeutics reports a significant net loss increase and a delay in Anaphylm's FDA approval, alongside a legal setback for Libervant, despite successful capital raises.
NASDAQ
AQST
Aquestive Therapeutics, INC
10-K: Aquestive Therapeutics Reports Mixed 2024 Results Amidst Libervant Legal Challenge
Aquestive Therapeutics' 2024 results highlight progress in proprietary pipeline development alongside challenges in commercial execution and a significant legal hurdle for its newly launched Libervant.
NASDAQ
AQST
Aquestive Therapeutics, INC
10-K: Aquestive Therapeutics Expands Libervant License, Files Pediatric NDA
Aquestive Therapeutics amended its license agreement with Pharmanovia to expand the territory for Libervant and filed an NDA for pediatric use of the drug.